BioNxt Solutions Inc. has launched a feasibility study to develop an oral thin film (ODF) formulation of Semaglutide, marking a significant step toward transforming how GLP-1 receptor agonists are delivered. Semaglutide, the active ingredient in blockbuster drugs like Ozempic®, Wegovy®, and Rybelsus®, is currently administered via injection or large oral tablets—both of which pose challenges for patient adherence and comfort. BioNxt’s ODF platform aims to offer a needle-free, rapidly dissolving alternative that can simplify administration and improve user experience, particularly for patients managing chronic conditions like diabetes and obesity.

The feasibility study will assess the compatibility of BioNxt’s proprietary thin film technology with Semaglutide’s complex peptide structure. Key objectives include evaluating drug loading capacity, film stability, and the integrity of the active pharmaceutical ingredient during formulation. If successful, the project could lead to a first-of-its-kind oral delivery format that enables efficient absorption of Semaglutide without the burden of injections or bulky pills. The study is also designed to support early-stage patent filings, strengthening BioNxt’s intellectual property position in the high-growth GLP-1 drug market.

With the global GLP-1 receptor agonist market projected to surpass USD 150 billion by 2030, the development of patient-centric delivery alternatives has become increasingly important. BioNxt’s ODF platform not only aligns with this trend but also holds potential for broader applications across other peptide-based therapeutics. As obesity, type 2 diabetes, and cardiovascular complications continue to rise, BioNxt’s innovation represents a timely and scalable solution—offering the promise of greater accessibility, better compliance, and improved outcomes in metabolic health care.